top of page
Gemini_Generated_Image_ju7wxmju7wxmju7w.png

Exclusive Services

At Essence MD Research, we are committed to advancing medical innovation through our comprehensive clinical trial services. We provide patients with access cutting-edge treatments, personalized care, and compassionate support throughout their research journey. For sponsors and CRO, our full-service trial management ensures rapid study start-up, effective patient recruitment, and adherence to regulatory compliance, all while maintaining high-quality data collection. We conduct every study integrity, precision, and care.

GSK 222725 ENDURA

Sandy Desert Texture

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

​​

The treatment period ranges from 52-104 weeks.

​

Follow-Up period: 9 weeks after exit visit.

​

Inclusion criteria: Age: ≥40 to ≤80 years of age, at the time of ICF; Blood Eosinophil Count (BEC); COPD diagnosis at least 1 year clinically 
documented; COPD assessment test (CAT) ≥10; Current or former cigarette smokers with history of cigarette smoking≥10 years; Optimized inhaler therapy;  Adjunctive COPD therapies; Weight: BMI ≥ 16 kg/m2; Male or eligible Female;  Capable of giving informed consent.

​

Exclusion criteria:  Asthma diagnosis; COPD stability; Lung resection; Pulmonary rehabilitation;  Oxygen; Cor Pulmonale; Chronic hypercapnia; Unstable cardiovascular disease or arrhythmia;  Vasculitis; Eosinophilic disease; Parasitic Infection;  Malignancy; . Immunodeficiency; Liver Disease;  Other concurrent medical condition; Previous exposure; Previous failure or nonresponse to antiIL5/5R or anti IL-4R/IL-13 treatment; . Other mAbs; Investigational medications;  Oral corticosteroids; Previous randomization; Concurrent enrollment in another clinical trial;  12-lead ECG at Screening V1; . Hypersensitivity; Non-compliance; Questionable validity of consent; Drug or alcohol abuse; Affiliation with investigator site;  Liver Safety exclusion.

​​

​

GSK 221672 BEconneCTD-ILD CTD

Gemini_Generated_Image_ju7wxmju7wxmju7w.png

A Phase 3, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).

​

The treatment period 52 weeks.

​

Follow-Up Period: 8 weeks after exit visit.

​

Inclusion criteria: Participant is 18 years of age inclusive, or older at the time of signing the informed consent; Documented diagnosis of RA, SLE, IIM, pSS, mCTD; Diagnosis of ILD on HRCT with disease extent of ≥10% of the whole lung (WL-ILD), as confirmed by central reader at screening; Evidence of ILD progression in the previous 24 months; Participant is capable and willing to self-administer the study medication.

​​

Exclusion criteria: Participants will be excluded if they have ILD other than CTD-ILD, systemic sclerosis, rapidly progressive disease, severe pulmonary impairment, significant pulmonary or systemic comorbidities, active or recent serious infections, tuberculosis, recent malignancy, major surgery, severe allergies or hypersensitivity reactions, neurological disorders such as PML, or significant psychiatric conditions including depression or suicide risk.

​

GSK 223977 VENTO Bronchiectasis Phase II

Desert Sand Dunes

 A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis” (“Study”) 

​

The treatment period: 48 weeks.

​​​

Inclusion criteria: Participants must be adults 18–85 years of age with a diagnosis of bronchiectasis confirmed by chest CT, a BMI between 18 and 35 kg/m², current sputum production, and adequate lung function (FEV₁ ≥30% predicted). Participants must also have a history of pulmonary exacerbations or uncontrolled respiratory symptoms and be able to provide informed consent.

​​

Exclusion criteria: Participants may not have a primary diagnosis of asthma or COPD or certain causes of bronchiectasis, including cystic fibrosis. Individuals with active respiratory infections, tuberculosis, or certain fungal or nontuberculous mycobacterial (NTM) infections, as well as those with a recent pulmonary exacerbation or acute respiratory infection, may be excluded. Other exclusions include certain uncontrolled medical conditions or significant heart, liver, or immune disorders, long-term oxygen therapy for more than 12 hours per day, and other conditions or treatments that may affect participant safety or study results.

​

BI 1305-0152 (FIBRONEER - ACT)

Intricate Coral Details

​A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)​.

​​

Treatment period: 52 weeks (Period A).

​

Follow-up period: Minimum of 5 days (+7 days).

 

Inclusion criteria: Adults aged 18 or older with fibrotic lung disease confirmed by HRCT (≥10% fibrosis), diagnosed within the past 3 years, with FVC ≥45% and DLCO ≥25% of predicted normal.

​

Exclusion criteria: Patients with IPF, autoimmune-ILD (except RA-ILD), sarcoidosis, organizing pneumonia, COVID-19-related ILD, or progressive pulmonary fibrosis (PPF); those eligible for approved ILD therapies, previously or currently treated with nerandomilast, nintedanib, or pirfenidone, or with FEV1/FVC below 0.7.

​​​​​

CSL Behring CSL787_2001 Site #84000652

Image by Marissa Rodriguez

A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis.​

​

Treatment period: 52 weeks.

​

Follow-up period: 4 weeks.

​

Inclusion criteria: Adults aged 18–85 with confirmed non-cystic fibrosis bronchiectasis (NCFB), able to produce sputum, with a history of pulmonary exacerbations requiring antibiotics and post-bronchodilator FEV1 above 35% predicted and at least 1 L.

​

Exclusion criteria: Patients with severe or uncontrolled asthma, bronchospasm or hypersensitivity to study treatment, other primary pulmonary disorders (including COPD, asthma, or diffuse panbronchiolitis), or recent antibiotic treatment within 4 weeks before baseline.

​

​

Kinaset Asthma Frevencitinib Phase II Site #SN0120267 / KN2147

Gemini_Generated_Image_ju7wxmju7wxmju7w.png

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

​

Treatment period: 12 weeks.

​​​

Inclusion criteria: Adults aged 18–75 with physician-diagnosed asthma for at least 12 months, BMI of 18–40 kg/m², and weight ≥40 kg. Participants must be on stable medium- or high-dose ICS/LABA therapy, have FEV1 between 40% and 80% predicted, demonstrate bronchodilator reversibility, and have experienced at least one asthma exacerbation in the past year.

​

Exclusion criteria: Current smokers or individuals with a smoking history of ≥10 pack-years, uncontrolled medical conditions, other respiratory diseases that may interfere with the study, history of cancer, active tuberculosis, or a positive TB screening test.

​

​

AMAZE 7

Image by Marissa Rodriguez

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

​​

Treatment period: 84 weeks.

​​​

Follow-up period: 8 weeks.

​

Inclusion criteria: Adults aged 18 or older with a BMI ≥30 kg/m² who are committed to losing at least 25% of their body weight within 84 weeks.

​

Exclusion criteria: Individuals with diabetes (HbA1c ≥6.5% or a history of type 1 or type 2 diabetes) or those treated with GLP-1-based medications or amylin analogues within the past year.

​

GSK 300629 PERSIST COPD-1

Sandy Desert Texture

​A study to investigate the efficacy and safety of GSK5784283 (felcorekibart) compared with placebo in participants with moderate to very severe COPD (PERSIST COPD-1)

​

Treatment period: minimum of 52 weeks up to a maximum duration of 78 weeks.

​

Follow-up period: 3 remote visits and a final on-site visit 60 weeks after the final IP administration.

 

Inclusion criteria: 40 to 80 years of age with 2 recorded BEC ≥ 150 cells/µL. Participants must be taking maintenance COPD treatment with inhaled triple therapy (as defined in Section 5.1) for at least 3 months prior to Screening Visit 1. Participants are required to have a history of ≥2 moderate or ≥1 severe COPD exacerbations within 12 months of screening.

​

Exclusion criteria: asthma, other significant lung diseases, recent respiratory infections or COPD exacerbations, certain medical conditions, prohibited medications or treatments, positive infectious disease tests, or conditions that may affect safety, compliance, or study participation.

​

GSK 300743 PERSIST ASTHMA-2

Sandy Desert Texture

​A study to investigate the efficacy and safety of GSK5784283 SC compared with placebo in 
participants with uncontrolled asthma (PERSIST ASTHMA-2)
​​

​

Treatment period: 52 weeks.

​

Follow up: Week 52 through Week 86.

​

Inclusion Criteria: Participants must have an ACQ-5 score ≥1 at randomization and demonstrate at least 9 days of compliance with eDiary entries and peak expiratory flow (PEF) measurements during the 14-day run-in period.

​

Exclusion Criteria: Participants with recent asthma exacerbations or clinically significant infections who have not returned to baseline for at least 10 days, changes in baseline asthma medication, or poor adherence to prescribed treatment during the run-in period.

​​​

​

GSK 219855 BLISSconneCTD-OLE

Sandy Desert Texture

​A study to investigate the long-term safety and 
efficacy of belimumab in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and other connective tissue diseases (CTD) (BLISSconneCTD-OLE).

​​

Treatment period: 52 weeks.

 

Follow-up: 8 weeks.

 

Inclusion criteria: Participants with systemic sclerosis-associated ILD (SSc-ILD) or other connective tissue disease-associated ILD (CTD-ILD) who completed a previous study through Week 52 without treatment failure. Participants must be able to receive subcutaneous injections, self-administer the study medication or have assistance, and meet informed consent and pregnancy prevention requirements, if applicable.

​

Exclusion criteria: Participants who discontinued treatment before Week 52, developed significant or uncontrolled medical conditions, experienced safety-related adverse events, have conditions that may affect drug safety or study results, had excessive radiation exposure, or had a prolonged QTc interval (>480 msec) at Week 52.

​

​

BI 1397-0018

Sandy Desert Texture

*

All Rights Reserved © 2035 by Essence MD Research LLC. Powered and secured by Wix.

bottom of page